Navigation Links
Stents as good as surgery for clogged carotid arteries
Date:2/26/2010

MAYWOOD, Il. -- The CREST trial that compared traditional surgery with less-invasive stenting to clear dangerously clogged carotid arteries in the neck is being called "seminal and robust."

The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) found that the safety and efficacy of both procedures are roughly equal. The trial, conducted throughout the United States and Canada, is one of the largest randomized stroke prevention trials ever.

Loyola University Medical Center is among the centers that participated in CREST.

"Our multidisciplinary team enrolled patients in both arms of this seminal and robust trial," said Dr. Jos Biller, one of the principal investigators at Loyola. "The data obtained at Loyola and other centers now will better inform doctors and patients about the relative benefits and risks of endarterectomy and stenting." Biller is chairman of the Department of Neurology at Loyola University Chicago Stritch School of Medicine. The other principal investigator at Loyola is Dr. Fred Leya, director of the cardiac catheterization lab.

Results were announced Feb. 26 at the 2010 International Stroke Conference in San Antonio. The study was funded by the National Institute of Neurological Disorders and Stroke and led by researchers at the Mayo Clinic in Jacksonville, Fla and the University of Medicine and Dentistry of New Jersey in Newark.

Carotid arteries on each side of the neck supply blood to the brain. As a patient ages, plaque can build up, causing the artery to stiffen and narrow. A patient can suffer a stroke if the artery becomes completely blocked. Or, bits of plaque can break off and travel to the brain and cause a mini stroke called a transient ischemic attack (TIA).

The traditional gold standard treatment is an endartectomy. A surgeon peels out the plaque deposit by removing the inner lining of the clogged artery. In the newer stenting procedure, a surgeon uses a catheter to deploy a stent (mesh tube). The stent expands inside the artery to increase blood flow.

CREST followed 2,502 participants, who were randomly assigned to receive an endarterectomy or a stenting. The overall safety and efficacy of the two procedures was largely the same. However, there were more heart attacks in the surgical group and more strokes in the stenting group.

"Both procedures are very safe and effective," said Dr. Mamdouh Bakhos, who performed endarterectomies in the trial. "Depending on a patient's age and medical condition, one procedure can have an advantage over the other. At Loyola, we offer both choices to patients." Bakhos is chairman of the Department of Thoracic and Cardiovascular Surgery.

Other Loyola physicians participating in the trial were Drs. Bernadette Aulivola and Peter Kalman, who perform endarterectomies; Drs. Robert Dieter and Fred Leya, who perform stenting procedures and neurologists Dr. Michael Schneck and Rima Dafer.

"The treatment strategy should be individualized to each patient, and take into consideration such factors as the patient's age and the type of blockage," Dieter said. "It also is very important to consider how much experience the hospital and the physician have in performing each procedure."


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Nanowire coating for bone implants, stents
2. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
3. Drug-Coated Stents Go Head to Head
4. Study Finds Benefits With Drug-Coated Stents
5. New Canadian study finds drug coated heart stents to be safe:
6. Aeon Bioscience Continues Development of Drug Eluting Stents
7. Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
8. Top10 research advances include studies on genetics and stem cell research, stents
9. Study looks at off-label use of biliary stents
10. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
11. Surgery Better Than Stents for Multiple Blockages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: